妊娠早期脂肪因子水平预测妊娠期糖尿病研究进展

doi:10.12280/gjfckx.20201168

摘要/Abstract

摘要：

妊娠期糖尿病（gestational diabetes mellitus,GDM）是一种妊娠过程中常见的并发症,其发病率正在逐年上升,对母儿近期及远期健康均有不良影响。虽然GDM的发病机制不明,但通过在妊娠早期筛查血清中高危因子以预测GDM的发生,对促进GDM的早期干预和减轻危害具有重要意义。目前研究发现,多种脂肪细胞因子在妊娠早期与GDM的发生风险增加有关,包括降低的脂联素、网膜素1、鸢尾素、趋化因子水平和升高的瘦素、抵抗素、内脂素、脂肪酸结合蛋白4、视黄醇结合蛋白4、促代谢因子水平。这些脂肪因子水平变化对未来GDM预测模型的建立提供理论支持。

关键词: 糖尿病,妊娠, 妊娠初期, 脂肪因子类, 预测, 脂联素, 抵抗素, 瘦素

Abstract:

As a common gestational complication, prevalence of gestational diabetes mellitus (GDM) is increasing steadily, leading to short- and long-term adverse outcomes for both mother and infant. The pathogenesis of GDM is unclear, however, screening biomarkers in maternal serum for predicting GDM in the first trimester is of great significance for early intervention to lessen the harm. Recent evidence suggests that some adipokines in the first trimester showed correlations with GDM development, including decreased levels of adiponectin, omentin-1, irisin, chemerin, and increased levels of leptin, resistin, visfatin, fatty acid-binding protein 4, retinol-binding protein 4 and betatrophin. These adipokines would help complete a predictive or early diagnostic model for GDM.

Key words: Diabetes,gestational, Pregnancy trimester,first, Adipokines, Forecasting, Adiponectin, Resistin, Leptin

楼海锋, 陈丹青. 妊娠早期脂肪因子水平预测妊娠期糖尿病研究进展[J]. 国际妇产科学杂志, 2021, 48(5): 494-498.

LOU Hai-feng, CHEN Dan-qing. Process of Adipokines in First Trimester for Predicting Gestational Diabetes Mellitus[J]. Journal of International Obstetrics and Gynecology, 2021, 48(5): 494-498.

参考文献 24

[1]	No authors listed. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus[J]. Obstet Gynecol, 2018,131(2):e49-e64. doi: 10.1097/AOG.0000000000002501. doi: 10.1097/AOG.0000000000002501
[2]	Plows JF, Stanley JL, Baker PN, et al. The Pathophysiology of Gestational Diabetes Mellitus[J]. Int J Mol Sci, 2018,19(11):3342. doi: 10.3390/ijms19113342. doi: 10.3390/ijms19113342
[3]	Francisco V, Ruiz-Fernández C, Pino J, et al. Adipokines: Linking metabolic syndrome, the immune system, and arthritic diseases[J]. Biochem Pharmacol, 2019,165:196-206. doi: 10.1016/j.bcp.2019.03.030. doi: S0006-2952(19)30116-9 pmid: 30910694
[4]	Madhu SV, Bhardwaj S, Jhamb R, et al. Prediction of Gestational Diabetes from First Trimester Serum Adiponectin Levels in Indian Women[J]. Indian J Endocrinol Metab, 2019,23(5):536-539. doi: 10.4103/ijem.IJEM_319_19. doi: 10.4103/ijem.IJEM_319_19 pmid: 31803593
[5]	Abell SK, Shorakae S, Harrison CL, et al. The association between dysregulated adipocytokines in early pregnancy and development of gestational diabetes[J]. Diabetes Metab Res Rev, 2017 Nov,33(8). doi: 10.1002/dmrr.2926. doi: 10.1002/dmrr.2926
[6]	Katsiki N, Mikhailidis DP, Banach M. Leptin, cardiovascular diseases and type 2 diabetes mellitus[J]. Acta Pharmacol Sin, 2018,39(7):1176-1188. doi: 10.1038/aps.2018.40. doi: 10.1038/aps.2018.40 pmid: 29877321
[7]	Bawah AT, Seini MM, Abaka-Yawason A, et al. Leptin, resistin and visfatin as useful predictors of gestational diabetes mellitus[J]. Lipids Health Dis, 2019,18(1):221. doi: 10.1186/s12944-019-1169-2. doi: 10.1186/s12944-019-1169-2
[8]	Thagaard IN, Krebs L, Holm JC, et al. Adiponectin and leptin as first trimester markers for gestational diabetes mellitus: a cohort study[J]. Clin Chem Lab Med, 2017,55(11):1805-1812. doi: 10.1515/cclm-2017-0427. doi: 10.1515/cclm-2017-0427 pmid: 28763297
[9]	Siddiqui K, George TP. Resistin role in development of gestational diabetes mellitus[J]. Biomark Med, 2017,11(7):579-586. doi: 10.2217/bmm-2017-0013. doi: 10.2217/bmm-2017-0013 pmid: 28685604
[10]	Hu SM, Chen MS, Tan HZ. Maternal serum level of resistin is associated with risk for gestational diabetes mellitus: A meta-analysis[J]. World J Clin Cases, 2019,7(5):585-599. doi: 10.12998/wjcc.v7.i5.585. doi: 10.12998/wjcc.v7.i5.585
[11]	Radzicka S, Pietryga M, Iciek R, et al. The role of visfatin in pathogenesis of gestational diabetes (GDM)[J]. Ginekol Pol, 2018,89(9):518-521. doi: 10.5603/GP.a2018.0088. doi: 10.5603/GP.a2018.0088 pmid: 30318580
[12]	Zhang W, Zhao D, Meng Z, et al. Association between circulating visfatin and gestational diabetes mellitus: a systematic review and meta-analysis[J]. Acta Diabetol, 2018,55(11):1113-1120. doi: 10.1007/s00592-018-1188-x. doi: 10.1007/s00592-018-1188-x
[13]	Tok A, Ozer A, Kanat-Pektas M, et al. The role of omentin in early pregnancy losses[J]. J Obstet Gynaecol, 2020,40(1):107-110. doi: 10.1080/01443615.2019.1606179. doi: 10.1080/01443615.2019.1606179
[14]	Alves JG, Souza A, Figueiroa JN, et al. Visceral Adipose Tissue Depth in Early Pregnancy and Gestational Diabetes Mellitus - a Cohort Study[J]. Sci Rep, 2020,10(1):2032. doi: 10.1038/s41598-020-59065-5. doi: 10.1038/s41598-020-59065-5
[15]	Tu WJ, Guo M, Shi XD, et al. First-Trimester Serum Fatty Acid-Binding Protein 4 and Subsequent Gestational Diabetes Mellitus[J]. Obstet Gynecol, 2017,130(5):1011-1016. doi: 10.1097/AOG.0000000000002310. doi: 10.1097/AOG.0000000000002310
[16]	Li L, Lee SJ, Kook SY, et al. Serum from pregnant women with gestational diabetes mellitus increases the expression of FABP4 mRNA in primary subcutaneous human pre-adipocytes[J]. Obstet Gynecol Sci, 2017,60(3):274-282. doi: 10.5468/ogs.2017.60.3.274. doi: 10.5468/ogs.2017.60.3.274
[17]	Torabi R, Ghourchian H. Ultrasensitive nano-aptasensor for monitoring retinol binding protein 4 as a biomarker for diabetes prognosis at early stages[J]. Sci Rep, 2020,10(1):594. doi: 10.1038/s41598-019-57396-6. doi: 10.1038/s41598-019-57396-6
[18]	Du C, Kong F. A Prospective Study of Maternal Plasma Concentrations of Retinol-Binding Protein 4 and Risk of Gestational Diabetes Mellitus[J]. Ann Nutr Metab, 2019,74(1):1-8. doi: 10.1159/000494888. doi: 10.1159/000494888
[19]	Jin C, Lin L, Han N, et al. Plasma retinol-binding protein 4 in the first and second trimester and risk of gestational diabetes mellitus in Chinese women: a nested case-control study[J]. Nutr Metab(Lond), 2020,17:1. doi: 10.1186/s12986-019-0425-9. doi: 10.1186/s12986-019-0425-9
[20]	Drewlo S, Johnson E, Kilburn BA, et al. Irisin induces trophoblast differentiation via AMPK activation in the human placenta[J]. J Cell Physiol, 2020,235(10):7146-7158. doi: 10.1002/jcp.29613. doi: 10.1002/jcp.29613
[21]	Wang P, Ma HH, Hou XZ, et al. Reduced plasma level of irisin in first trimester as a risk factor for the development of gestational diabetes mellitus[J]. Diabetes Res Clin Pract, 2018,142:130-138. doi: 10.1016/j.diabres.2018.05.038. doi: 10.1016/j.diabres.2018.05.038
[22]	Sancak S, Aydın H, Sargin M, et al. Serum Irisin Level Increases Throughout The Gestational Period And It Does Not Play A Role In Development Of Gestational Diabetes Mellitus[J]. Acta Endocrinol(Buchar), 2017,13(4):393-399. doi: 10.4183/aeb.2017.393. doi: 10.4183/aeb.2017.393
[23]	Yang X, Quan X, Lan Y, et al. Serum chemerin level during the first trimester of pregnancy and the risk of gestational diabetes mellitus[J]. Gynecol Endocrinol, 2017,33(10):770-773. doi: 10.1080/09513590.2017.1320382. doi: 10.1080/09513590.2017.1320382
[24]	Huang Y, Chen X, Chen X, et al. Angiopoietin-like protein 8 in early pregnancy improves the prediction of gestational diabetes[J]. Diabetologia, 2018,61(3):574-580. doi: 10.1007/s00125-017-4505-y. doi: 10.1007/s00125-017-4505-y pmid: 29167926